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Abstract
Background: Toxoplasma gondii can infect all warm-blooded animals including humans. Infection with T. gondii is
probably the leading cause of posterior uveitis in humans and the most comment route of transmission is raw and
undercooked meat from infected animals. T. gondii calcium-dependent protein kinase 1 (TgCDPK1) plays a critical
role in direct parasite motility, host-cell invasion, and egress.
Methods: We constructed a DNA vaccine expressing TgCDPK1 inserted into eukaryotic expression vector pVAX I
and evaluated the immune protection induced by pVAX-CDPK1 in Kunming mice. Mice immunized with pVAX-
CDPK1 intramuscularly and/or with a plasmid encoding IL-15 and IL-21 (pVAX-IL-21-IL-15). The immune responses
were analyzed including lymphoproliferative assay, cytokine, antibody measurements, lymphocyte surface markers
by flow cytometry and protective efficacy were measured as survival and cysts numbers after challenge 1 to
2 months post vaccination.
Results: Immunization with pVAX-CDPK1 or pVAX-IL-21-IL-15 alone developed strong humoral responses and Th1
type cellular immune responses, and the significantly (P < 0.05) increase of both the percentages of CD4+ and CD8
+ T cells compared with all the controls (blank control, PBS, and pVAX). Co-injection of pVAX-IL-21-IL-15 significantly
increased humoral and cellular immune responses compared to the group of pVAX-CDPK1 or pVAX-IL-21-IL-15.
Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05)
increased survival time (19.2 ± 5.1 days) compared with pVAX-CDPK1 (17.3 ± 4.3 days) or pVAX-IL-21-IL-15 (12.0 ±
2.0 days) alone, and pVAX-IL-21-IL-15 + pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in
contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).
Conclusions: TgCDPK1 is identified to be a promising vaccine candidate for inducing a strong humoral and cellular
response against T. gondii infection, and thus synergistic of mIL-21 and mIL-15 can induce non-specific immune
responses, but also facilitate specific humoral as well as cellular immune responses elicited by DNA vaccine against
acute and chronic T. gondii infection in mice.
Keywords: Toxoplasma gondii, Toxoplasmosis, TgCDPK1, pVAX-IL-15-IL-21, DNA vaccine, Protective immunity
* Correspondence: huangsiyang@caas.cn; xingquanzhu1@hotmail.com
1State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of
Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research
Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province
730046, PR China
2College of Animal Science and Veterinary Medicine, Heilongjiang Bayi
Agricultural University, Daqing, Heilongjiang Province 163319, PR China
Full list of author information is available at the end of the article
© 2014 Chen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Chen et al. BMC Infectious Diseases 2014, 14:487
http://www.biomedcentral.com/1471-2334/14/487
Background
Toxoplasma gondii can invade a wide range of vertebrate
hosts including humans, leading to a variety of clinical
infections in humans [1-4]. T. gondii infection pose ser-
ious public safety issues [5,6]. T. gondii can also cause
abortion in all types of livestock, such as sheep and
goats, and infected meat can serve as a source of trans-
mission to humans [7-9].
No drugs which effectively eliminate the parasite are
available, so the current development of an effective vac-
cine against T. gondii infection is a promising alternative
to control toxoplasmosis in animals, and also an effect-
ive vaccine preventing infection in animals used for hu-
man consumption would block the main transmission
route to humans [10,11]. Although several types of vac-
cineshave been developed including genetically engineer-
ing vaccines, subunit vaccines, especially, a live and
attenuated vaccine of T. gondii S48 strain named Toxo-
Vax has been licensed and used in farm animals, but it
has limitations of poor efficacy or biosafety concerns
[10,11]. Most efforts have been made on DNA vaccines
due to their capacity to induce a Th1-type immune re-
sponse including a strong CD8+ cytotoxic T-lymphocyte
(CTL) response [12-14].
A group of plant-like calcium-dependent protein ki-
nases (CDPKs), belonging to a superfamily of kinases,
are in charge of the calcium signaling cascades of plants,
and some ciliates [15]. In apicomplexans, CDPKs have
been implicated in calcium-signal transduction involving
in some events such as gliding motility or egress [16].
T. gondii CDPK1 protein is conserved among apicom-
plexans, involved in important biological function, in-
cluding the regulation of the parasite’s life cycle at stages
dependent on microneme secretion, and it is recognized
as the key regulator of calcium dependent exocytosis
and acts in calcium-dependent secretion of specialized
organelles called micronemes, which play a critical role
in direct parasite motility, host-cell invasion, and egress
[17], but also CDPKs have been identified in plants, cili-
ates and apicomplexans but not expressed by mammals,
which represents validated target that may be exploitable
for vaccine candidate against T. gondii.
Improvement of the efficacy of DNA vaccines may be
achieved by administration of cytokines as adjuvants. Re-
cently, genetic adjuvants using the cytokines with the syn-
ergy of IL-21 and IL-15 have been demonstrated to induce
enhanced protective immunity in animal models against in-
fectious disease [18-20]. Also, in our previous studies, we
have found that co-administration of IL-21 and IL-15 could
be used as adjuvants and boost antigen-specific humoral as
well as Th1 cellular immune responses induced by DNA
vaccine against T. gondii infection [21]. In this study, we
constructed a eukaryotic plasmid, pVAX-CDPK1, and ex-
amined the immunogenicity, and protective immune effect
of this DNA vaccine in Kunming mice against T. gondii in-
fection. Co-administration of eukaryotic plasmid encoding
both IL-21 and IL-15 with pVAX-CDPK1 was used as adju-
vants to enhance the Th1 immune response and increase
the of protective T. gondii immunity.
Methods
Mice and parasites
Six to eight week old female Kunming mice were pur-
chased from Lanzhou University Laboratory Animal Cen-
ter (Lanzhou, China). All mice used for the experiments
were raised and handled in strict accordance with the
Good Animal Practice requirements of the Animal Ethics
Procedures and Guidelines of the People’s Republic of
China. This study was approved by the Animal Ethics
Committee of Lanzhou Veterinary Research Institute,
Chinese Academy of Agricultural Sciences (Approval No.
LVRIAEC2011-012).
Tachyzoites of the highly virulent RH strain of T. gondii
were preserved in our laboratory (Laboratory of Parasit-
ology, Lanzhou Veterinary Research Institute, Chinese
Academy of Agricultural Sciences), and harvested from the
peritoneal fluid of mice, washed by centrifugation, and
then suspended in sterile phosphate-buffered saline (PBS).
The cysts of the PRU strain were obtained from the brains
of orally infected Kunming mice, and maintained by
monthly passage.
Preparation of Toxoplasma lysate antigen (TLA)
Purified tachyzoites of T. gondii RH strain were dis-
rupted by three cycles of freezing at −20°C and thawing,
and then sonicated on ice at 60 W/s. The prepared cel-
lular lysate was centrifuged for 30 min at 10, 000 × g at
4°C, and the supernatants were pooled, sterile filtered
with 0.2 μm sterile nitrocellulose filters (Sartorius). Fi-
nally, the TLA concentration was determined via the
Bradford method using bovine serum albumin (BSA) as
the standard, aliquoted and stored at −70°C until use.
Construction of DNA vaccine plasmid
Total RNA was prepared from the tachyzoites of RH
strain using TRIzol reagent (Invitrogen) according to the
manufacturer’s instructions, and the coding sequences of
TgCDPK1 (1,749 bp, GenBank accession no. AF333958.1)
were obtained by RT-PCR amplification from total RNA
using designed specific primers (forward primer: 5′-CG
GGGTACCATGGGGCAGCAGGAAAGCAC-3′, reverse
primer: 5′-GCTCTAGATTAGTTTCCGCAGAGCTTCA
AGA-3′), in which Kpn I and Xba I restriction sites were
introduced and underlined. Followed by ligation the ob-
tained RT-PCR product with pMD18-T vector (TaKaRa,
China), the TgCDPK1 fragment cleaved from pMD-
CDPK1 by Kpn I/Xba I were subcloned into the corre-
sponding sites of pVAX I (Invitrogen) using T4 DNA
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ligase and generated plasmid pVAX-CDPK1. All recom-
binant plasmids were propagated in Escherichia coli DH5α
and confirmed by specific PCR, restriction analysis and
DNA sequencing.
The recombinant plasmids were purified from trans-
formed Escherichia coli DH5α cells by anion exchange
chromatography (EndoFree plasmid giga kit, Qiagen Sci-
ences, Maryland, USA) following the manufacturer’s in-
structions, dissolved in sterile endotoxin-free TE buffer
and stored at −20°C until use. Plasmid pVAX-IL-21-IL-
15 was prepared and preserved previously in our labora-
tory. The concentration of recombinant plasmids was
determined by spectrophotometer at OD260 and OD280.
Expression of pVAX-CDPK1 plasmid in vitro
The recombinant plasmid pVAX-CDPK1 transfection into
Marc-145 cells was performed using lipofectamine™ 2000
reagent (Invitrogen) as instructed by the manufacturer.
In brief, forty eight hours post-transfection, cells were
processed for indirect immunefluorescence assay (IFA)
followed by incubation with goat anti-T. gondii tachyzoites
polyclonal antiserum and a FITC-labeled donkey-anti-goat
IgG antibody (Proteintech Group Inc., Chicago, USA).
The specific fluorescence was examined through a Zeiss
Axioplan fluorescence microscope (Carl Zeiss, Germany).
Marc-145 cells transfected with empty pVAX I served as
the negative control.
DNA immunization and challenge infection
Six groups (35 mice in each group) were intramuscularly
injected twice at 2-week intervals in three immuniza-
tions (at weeks 0, 2 and 4) with 100 μg pVAX-CDPK1
DNA in 100 μl sterile PBS, 100 μg pVAX-CDPK1 +
pVAX-IL-21-IL-15 DNA in 100 μl sterile PBS, 100 μg
pVAX/IL-21/IL-15 DNA in 100 μl sterile PBS, 100 μg
the empty vector pVAX, PBS (100 μl/each), respectively,
and one group of mice was not inoculated to constitute
blank control. Blood were collected at 0, 2, 4 and 6 weeks
to analyze for specific antibodies. Splenocytes were asep-
tically harvested for lymphocyte proliferation assay, cyto-
kine measurements, and flow cytometric analysis. This
analysis was performed in three independent experiments.
Two weeks after the last immunization, 15 mice per
group were challenged intraperitoneally (IP) with 1 × 103
tachyzoites of the RH strain. The survival time for each
mouse and the percentages of mice survived were re-
corded until a fatal outcome for all animals. In addition,
10 mice per group were inoculated orally with 20 cysts of
the PRU strain at day 14th after the third immunization,
and observed mice daily for mortality. Four weeks after
the PRU strain challenge, surviving mice were sacrificed
and their brains were removed. Each brain was homoge-
nized in 1 ml PBS. The mean number of cysts per brain
was determined by counting three samples of 10 μl
aliquots of each homogenized brain under an optical
microscope. This analysis was performed in three inde-
pendent experiments.
Antibody analysis
Levels of IgG, IgG1 and IgG2a antibody in serum were
determined by ELISA using SBA Clonotyping System-
HRP Kit according to the manufacture’s instruction
(Southern Biotech Co., LTD, Birmingham, USA). Micro-
titer plates were coated with capture antibody (10 μg/ml;
provided by the commercial Kit) in 100 μl of phosphate
buffered saline (PBS; pH7.4) at 4°C overnight. Plates were
washed twice with PBS plus 0.05% Tween20 (PBS-T) and
blocked with PBS containing 1% BSA (PBS-1% BSA) for
1 h at room temperature. After being washed with PBS-T,
the wells were incubated with 100 μl of horseradish-
peroxidase (HRP) conjugated anti-mouse IgG (diluted in
1:250 in PBS-1% BSA), anti-mouse IgG1 or IgG2a (1:500)
at 37°C for 60 min. After incubation with 100 μl substrate
solution (pH4.0) (1.05% citrate substrate buffer; 1.5%
ABTS; 0.03% H2O2) for 20 min, the absorbance was mea-
sured at 405 nm using an ELISA reader (Bio-TekEL × 800,
USA). All samples were run in triplicate.
Lymphocyte proliferation assays
Two weeks after the final immunization, splenocytes
were harvested from 3 mice of each group as described
previously [21]. After the erythrocytes were lysed using
erythrocyte lysis buffer (0.15 M NH4Cl, 1.0 M KHCO3,
0.1 mM EDTA, pH 7.2), the splenocytes were resus-
pended in DMEM medium supplemented with penicil-
lin, streptomycin and 10% fetal calf serum (FCS). The
cells were counted with a haemocytometer by trypan
blue dye exclusion technique and distributed at a density
of 5 × 105 cells in 96-well costar plates with stimulated
by TLA (10 μg/ml), concanavalin A (ConA; 5 μg/ml;
Sigma; positive control) or medium alone (negative con-
trol) at 37°C in a 5% CO2. The proliferative activity was
measured using a 3-(4,5-dimethylthylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT, 5 mg/ml, Sigma) dye
assay, as previously described [22]. The stimulation index
(SI) was calculated as the ratio of the average OD570 value
of wells containing TLA-stimulated cells (OD570TLA) to
the average OD570 value of wells containing only cells with
medium (OD570M). All experimental and control samples
were run in triplicate.
Cytokine assays
Splenocytes from each group were harvested and cul-
tured with TLA in flat-bottom 96-well microtiter plates
as described for the lymphocyte proliferation assay. Cul-
ture supernatants were harvested and detected for IFN-γ
at 96 h, IL-2 at 24 h, IL-4 at 24 h and IL-10 at 72 h ac-
cording to a protocol of the manufacture’s instruction.
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Cytokine concentrations were determined using com-
mercial ELISA kits (Biolegend, USA) by reference to
standard curves constructed with known amounts of
mouse recombinant IFN-γ, IL-2, IL-4 and IL-10. The
sensitivity limits for the assays were 8.0 pg/ml for IFN-γ,
0.9 pg/ml for IL-2, 0.5 pg/ml for IL-4, 23.8 pg/ml for IL-
10, respectively. The analysis was performed with the
data from three independent experiments.
Cell surface staining of splenic lymphocytes
After viability determination of harvested lymphocytes
from each group using 0.04% trypan blue (viability >
90%) and adjusted cell concentration to 1 × 106 cells/ml
in PBS containing 2% FBS, the cells were incubated with
surface markers including phycoerythrin (PE)-labeled
anti-mouse CD3, Allophycocyanin (APC)-labeled anti-
mouse CD4 and fluorescein isothiocyanate (FITC)-la-
beled anti-mouse CD8 (eBioscience) at 4°C for 30 min in
the dark. Followed by washed by 2 ml PBS and then
fixed with FACScan buffer (PBS containing 1% FCS and
0.1% Sodium azide) and 2% paraformaldehyde, the cul-
tures were analyzed of fluorescence profiles on a FACS-
can flow cytometer (BD Bio-sciences) by SYSTEM II
software (Coulter).
Statistical analysis
All statistical analyses were performed by SPSS13.0 Data
Editor (SPSS Inc., Chicago, IL, USA). The differences of
the data (e.g. antibody responses, lymphoproliferation
assays and cytokine production) between all the groups
were compared by one-way ANOVA. The results in
comparisons between groups were considered different
if P < 0.05.
Results
Identification of the expressed product by IFA
Expression of recombinant plasmid (pVAX-CDPK1)
in vitro was analyzed by IFA at 48 h post-transfection,
and specific green fluorescence was observed in Marc-
145 cells transfected with pVAX-CDPK1, whereas no
fluorescence was observed in the cells transfected with
pVAX I (Additional file 1: Figure S1). The results showed
that recombinant TgCDPK1 protein was successfully
expressed in Marc-145 cells.
Humoral response induced by DNA immunization
In order to evaluate the level of antibody induced by DNA
immunization, we detected the total IgG followed by three
times immunization and thus distribution of IgG1 and
IgG2a isotypes two weeks after last immunization. As
results, in contrast to PBS, pVAX I, or blank controls, a
significant antibody responses corresponding to total anti-
bodies including IgG, IgG1and IgG2a (P < 0.05) were
induced in immunized mice including the groups of
pVAX-CDPK1, pVAX-IL-21-IL-15 and pVAX-CDPK1
plus pVAX-IL-21-IL-15 (Figure 1A and B). The highest
antibody levels were observed in co-injection of pVAX-IL-
21-IL-15 and pVAX-CDPK1 in mice, and thus the increase
of antibody levels occurred with successive DNA immuni-
zations (Figure 1A).
The distribution of IgG1 and IgG2a isotypes was ana-
lyzed two weeks after the last immunization. Both IgG1
and IgG2a were detected in the sera of mice immunized
with pVAX-CDPK1, pVAX-IL-21-IL-15 and pVAX-
CDPK1 plus pVAX-IL-21-IL-15, but a predominance of
IgG2a over IgG1 (Figure 1B), but also co-injection of
pVAX-IL-21-IL-15 with pVAX-CDPK1 significantly in-
creased the ratio (P < 0.05). These results suggest that
the specific humoral response and Th1 type immune re-
sponse were elicited by DNA immunization and further
enhanced by co-adminitrsation of plasmids coding for
IL-15 and IL-21.
Cellular immune responses
In order to analyze whether the spleen cells has prolifer-
ated, and even produced immunological memory, and
thus the percentages of T cell subpopulation after T cell
proliferation followed by DNA immunization, we have
detected the proliferation Stimulation index (SI) and the
percentages of CD4+ and CD8+ T cells in the spleen of
immunized mice. As results, SI, in spleen cells from
mice immunized with pVAX-CDPK1 or pVAX-IL-21-IL-
15 alone was significantly higher in contrast to that with
pVAX I and PBS groups, but there was no any signifi-
cant different among three control groups (P > 0.05).
While co-inject pVAX-IL-21-IL-15 with pVAX-CDPK1
to mice, the level of splenocyte proliferation was further
increased (P < 0.05) (Table 1).
T cell mediated cellular immune response after DNA
vaccination were analyzed using flow cytometry analysis
of the percentages of CD4+ and CD8+ T cells in the
spleen of immunized mice. As depicted in Figure 2, the
percentage of CD3 + CD8 + CD4-T cells and CD3 + CD4
+ CD8-T cells were significantly increased in pVAX-
CDPK1 or pVAX-IL-21-IL-15 immunized mice com-
pared with PBS, pVAX I or the blank control groups,
and thus the most increase presented in pVAX-CDPK1
plus pVAX-IL-21-IL-15. There was no significant differ-
ent between three control groups (P > 0.05).
Production of cytokines by spleen cells
In order to analyze the type and level of T cell response,
we detected the levels of Th1 and Th2 type cytokines.
As results, a significant increase in secreted IFN-γ and
IL-2 were detected in mice immunized with pVAX-
CDPK1 or pVAX-IL-21-IL-15 alone (Table 1), and the
largest amounts of both two cytokines were produced in
mice immunized with pVAX-CDPK1 plus pVAX-IL-21-
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IL-15 in contrasted with that in the pVAX I, PBS and
the blank controls (P < 0.05). Furthermore, small
amounts of IL-4 and IL-10 were also secreted from sple-
nocytes stimulated by TLA in vitro in all immunized
mice compared to the control groups (P < 0.05).
Assessment of protective efficacy of DNA immunized
mice against T. gondii
In order to analyze the protective efficacy of DNA immu-
nized mice against T. gondii, we assess the survival time
after acute infection with 103 tachyzoites of the virulent
RH strain, and brain cysts after chronic infection with 10
PRU strain. As results, survival curves of different groups
of mice are shown in Figure 3. Mice immunized with
pVAX-CDPK1 (17.3 ± 4.3 days) or pVAX/IL-21/IL-15
(12.0 ± 2.0 days) significantly prolonged survival time after
challenge with 103 tachyzoites of the virulent RH strain in
comparison to mice in groups of pVAX I, PBS and blank
control, but there was significant difference of survival
time between the group of pVAX-CDPK1 and pVAX/IL-
21/IL-15 (P < 0.05). Co-administration with pVAX-CDPK1
and pVAX/IL-21/IL-15 enhanced the survival time of the
immunized mice (19.2 ± 5.1 days) in contrast to the group
of pVAX-CDPK1 or pVAX/IL-21/IL-15 (P < 0.05). All con-
trol mice died within 6 days after challenge, and no signifi-
cant difference was observed among these control groups
(P > 0.05). Similar to the results of challenge with RH
strain, the immunized groups challenged with PRU strain
cysts showed a significant reduction in the number of
cysts in the brain (P < 0.05) (Table 2).
Discussion
Despite some plasmids DNA expressing MIC13, GRA7,
IMP1, and eIF4A have been demonstrated to be vaccine
candidates against T. gondii infection [23-26], the con-
structs have not been able to induce complete protection
and new vaccine constructs using both multiple antigens
but also new adjuvants need to be identified. In the
present study, an eukaryotic plasmid expressing TgCDPK1
was evaluated against T. gondii infection in Kunming
mice model. The results showed that intramuscular
immunization with pVAX-CDPK1 could elicit specific
humoral and cellular immune responses, resulting in par-
tial protective immunity against T. gondii RH (type I) and
Figure 1 Humoral response in Kunming mice induced by DNA vaccination. (A). Determination of IgG antibodies in the sera of Kunming mice
immunized with pVAX-CDPK1, pVAX-IL-21-IL-15, pVAX-CDPK1 + pVAX-IL-21-IL-15, pVAX I, PBS and blank controls on weeks 0, 2, 4, 6. (B). Determination
of IgG subclass profiles (IgG1 and IgG2a) in sera of the immunized mice two weeks after the last immunization. Results are expressed as mean of the
OD405 ± S.E. (n = 3) and statistically significant differences (P < 0.05) are indicated by (*).
Table 1 Cytokine production by splenocytes of immunized Kunming mice after stimulation by Toxoplasma lysate
antigen (TLA)
Group (n = 3) Cytokine production (pg/ml) Proliferation
(SI)IFN-γ IL-2 IL-4 IL-10
pVAX-CDPK1 + pVAX-IL-21-IL-15 867.78 ± 15.63A* 532.54 ± 23.06A 154.44 ± 11.16A 131.04 ± 10.31A 5.57 ± 0.01A
pVAX-IL-21-IL-15 505.12 ± 32.72B 314.77 ± 27.06B 105.15 ± 16.82B 96.54 ± 20.03B 3.79 ± 0.05B
pVAX-CDPK1 563.65 ± 12.97C 353.12 ± 10.93C 111.94 ± 8.90B 109.72 ± 8.65B 4.19 ± 0.14C
pVAX I 53.02 ± 3.73D 52.04 ± 1.43D 51.01 ± 1.08C 51.13 ± 1.70C 1.05 ± 0.00D
PBS 52.92 ± 2.73D 51.49 ± 2.67D 49.84 ± 1.37C 50.20 ± 1.24C 1.04 ± 0.07D
Control 52.53 ± 2.43D 51.56 ± 1.43D 49.50 ± 1.79C 49.75 ± 1.16C 1.03 ± 0.03D
SI stimulation index.
Splenocytes from 3 mice were harvested 2 weeks after the last immunization.
Values for IFN-γ are after 96 h, values for IL-2 and IL-4 are after 24 h, and values for IL-10 are after 72 h.
*The same superscript letter “D” on the shoulders of experimental data means no statistically significant difference (P > 0.05) among different experimental
groups from the same measurement, while different letter including A, B, C means statistically significant difference among different experimental groups from
the same measurement (P < 0.05).
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PRU (type II) strains challenge, associated with an in-
creased survival time (17.3 ± 4.3 days, P < 0.05) and
45.7% cyst reduction significantly (P < 0.05) in contrast
with the control mice. Our unpublished data showed
that the CDPK1 gene is conserved between Type I
and Type II T. gondii strains, which is expressed in the
bradyzoite as well as the tachyzoite stage. Therefore,
we expect that the immune respose against CDPK1
will provide cross-protection between different T.gondii
genotypes.
Protective immunity against T. gondii is highly dependent
on CD8+ T cells mediated immune responses, but also ef-
fective cellular Th1-biased response and antibodies served
as mediators of protection [27-30]. In this study, we
first measured humoral immune responses association
with the IgG and IgG subclass induced by DNA
immunization with pVAX-CDPK1. Similar to those pre-
vious studies [23,24,31], vaccination with pVAX-CDPK1
induced high specific antibody titers in sera by ELISA
assay, and thus elicited the ratio of IgG2a to IgG1 titers,
indication of a mixed Th1/Th2 response.
Both IFN-γ and IL-2 secretion were significantly in-
creased in splenocytes from pVAX-CDPK1 immunized
mice and low levels of IL-4 and IL-10 was also produced
in contrast with the controls, demonstrating a Th1-
biased cellular immune response, but also emphasized
Figure 2 Detection of lymphocyte subpopulations using fluorescence assisted flow cytometry (FACS). (A) The percentages of CD3+ CD4+
CD8-T lymphocytes (CD3 gated) in mice spleen cells. (B) The percentages of CD3+ CD8+ CD4-T lymphocytes (CD3 gated) in mice spleen cells.
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again the activation of an appropriate T helper response
with high levels of Th1 and low levels of Th2 type cyto-
kines could be contributed to prevent CD4+ T cell-
mediated severe immunopathology during the acute and
chronic stage of T. gondii invasion [30].
It is well established that infection with T. gondii nat-
urally drives a potent cellular immune responses, espe-
cially T cell immune response that is critical to control
the infection in mice model [30,32]. In this study, we
found that cellular immune responses were activated by
intramuscularly immunization with pVAX-CDPK1, using
the MTT assay. Similar to the results from MIC13 and
CDPK3 vaccination [24,31], DNA immunization with
pVAX-CDPK1 induced the significantly increased per-
centage of both CD4+ and CD8+ T cells in contrast to
control groups, suggesting that the DNA vaccination in-
duced the activation of CD4+ and CD8+ T cells, which
may contribute to the synergistic effect on the T cell me-
diated cytotoxic T cell response. Therefore, these results
mentioned above have indicated that pVAX-CDPK1 was
a good DNA vaccine, eliciting the high levels of humoral
and even Th1-biased immune responses, just like our
previous studies focused on DNA vaccines including
eIF4A [23], MIC13 [24], and CDPK3 [31], but these
DNA vaccines using single antigen have not induced
complete protection, which could be ascribed to a theory
that DNA vaccines based on a single antigen have few
lymphocyte binding sites and are restricted largely by
the major histocompatibility complex (MHC), leading to
mount an effective immune response against T. gondii
infection difficultly [33].
Nevertheless, it has been recognized that DNA vaccine
based on a single antigen can only induce limited im-
munity to T. gondii, but the consequences of effective
immune responses to DNA vaccines can be further aug-
mented by co-delivery of cytokine adjuvants [34,35].
Similar to adjuvants including IL-12, IL-18 and IL-15
[18], the addition of cytokine genes combined with IL-
21 and IL-15 can facilitate the efficacy of potential DNA
vaccines against infectious disease [19,20]. Moreover, in
our previous studies [21], we have found that the syn-
ergy of rIL-15 and rIL-21 genes could augment the
Figure 3 Protection of Kunming mice against T. gondii infection. Survival curves of mice immunized with pVAX-CDPK1 (17.3 ± 4.3 days),
pVAX-IL-21-IL-15 (12.0 ± 2.0 days), pVAX-CDPK1 + pVAX-IL-21-IL-15 (19.2 ± 5.1 days), pVAX I, PBS and blank controls after lethal challenge with 1 ×
103 tachyzoites of virulent T. gondii RH strain 2 weeks after the last immunization. Each group had 15 mice. Three control groups (PBS, pVAX I and
blank control) had 0% survival at day 6. The same letter in front of experimental group means no statistically significant difference (P > 0.05)
between different experimental groups from the same measurement, while different letter means statistically significant difference (P < 0.05).
Table 2 Mean cyst burden per mouse brain 4 weeks after
challenge with 20 cysts of Toxoplamsa gondii strain PRU
per mouse
Group (n = 3) No. of brain cysts
(Means ± S.D.)
% reduction*
Control 3117 ± 140A** -
PBS 3067 ± 125A 1.6
PVAX I 3067 ± 125A 1.6
pVAX-CDPK1 1758 ± 150B 45.7
pVAX-IL-21-IL-15 1692 ± 111B 43.6
pVAX-CDPK1 + pVAX-IL-21-IL-15 850 ± 104C 72.7
*The reduction of brain cysts were from the values for the blank
control group.
**The same superscript letter means no statistically significant difference
(P > 0.05) between different experimental groups, whereas different
superscript letters mean statistically significant difference among different
experimental groups from the same measurement (P < 0.05).
A The superscript letter A means no statistically significant difference (P > 0.05)
between the groups of pVAX I, PBS and control.
B The superscript letter B means no statistically significant difference (P > 0.05)
between the groups of pVAX-CDPK1 and pVAX-IL-21-IL-15, but it means
significant differences of the No. of brain cysts in these two groups in contrast
to the control group.
C The superscript letter C means significant differences of the No. of brain
cysts in the group of pVAX-IL-21-IL-15 + pVAX-CDPK1 in contrast to the
groups of pVAX-CDPK1 and pVAX-IL-21-IL-15 (P < 0.05).
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efficacy of DNA vaccine in the induction of Th1-bised
response, and thus pVAX/mIL-21/mIL-15 alone could
induced strong immune responses resulting in protective
efficacy. So, we choose pVAX/mIL-21/mIL-15 as an ad-
juvant in pVAX-CDPK1 DNA vaccine in the present
study. In this study, codelivery both IL-21 and IL-15 as
an adjuvant in DNA vaccines could significantly enhance
the humoral and Th1-driven antigen-specific T helper
immune responses induced by pVAX-CDPK1, facilitating
protective immunity against toxoplasmosis in the mice
model, which is was consistent with the results of previ-
ous studies that used both IL-21 and IL-15 as an adju-
vant in DNA vaccines [19,20].
We also found that the administration of pVAX-IL-21-
IL-15 alone elicited a considerable non-specific protect-
ive immunity equivalent with the levels induced by
pVAX-CDPK1, which emphasized again that cytokine
adjuvant, pVAX-IL-21-IL-15 could act as immunothera-
peutic modulation used for T. gondii vaccines [21].
Taken together, the cytokines with the synergy of IL-21
and IL-15 appears to be a broadly effective genetic
adjuvant that could be used in DNA vaccines against
T. gondii, but this combination appears to induce en-
hanced immune sensitization as adverse effects asso-
ciated with IL-15 and IL-21 adjuvanted vaccinations or
immunotherapies, leading to increased risks of auto-
immunity or a variety of immune-mediated problems
[36]. Therefore, we need to explore these possibilities in
further investigation in detail.
Conclusion
In summary, our study demonstrates that pVAX-CDPK1
is a novel vaccine candidate, with the ability to elicit
humoral and cellular immunity to T. gondii infection and
induce partial protection after challenge. The use of a
plasmid expressing IL-21 and IL-15 as an adjuvant have
successfully enhanced the immunoprotective effect of
TgCDPK1, and suggest that further studies are warranted
to evaluate immune-enhancing effect of these genetic ad-
juvants (cytokines) in other apicomplexan parasites.
Additional file
Additional file 1: Figure S1. Indirect immunofluorescence (IFA)
detection of TgCDPK1 expression in Marc-145 cells 48 h post-transfection.
(A) Marc-145 cells were transfected with pVAX-CDPK1; (B) empty vector
pVAX I.
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